This study describes the identification of an antibiotic class acting via LpxH, involved in lipopolysaccharide synthesis having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.